Importance of blood pressure control in left ventricular mass regression

Journal of the American Society of Hypertension

Volumn 4, Issue 6, 2010, Pages 302-310

  Miller, Alan B ^a   Reichek, Nathaniel ^b,c   St John Sutton, Martin ^d   Iyengar, Malini ^e   Henderson, Linda S ^e   Tarka, Elizabeth A ^e   Bakris, George L ^f  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ST FRANCIS HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Carvedilol; Hypertension; Left ventricular hypertrophy

Indexed keywords

ALBUMIN; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALLEL DESIGN; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINOPHARYNGITIS; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARBAZOLES; CREATININE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LISINOPRIL; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; PROPANOLAMINES; UNITED STATES;

EID: 78649951376     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2010.09.003     Document Type: Article

References (44)

1. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
2. B.A. Vakili, P.M. Okin, and R.B. Devereux Prognostic significance of left ventricular hypertrophy Am Heart J 141 2001 334 341
3. G. Schillaci, P. Verdecchia, C. Porcellati, O. Cuccurullo, C. Cosco, and F. Perticone Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension Hypertension 35 2000 580 586
4. D. Levy, K.M. Anderson, D. Savage, W.B. Kannel, J.C. Christiansen, and W.P. Castelli Echocardiography detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study Ann Intern Med 108 1988 7 13
5. M.A. Quinones, B.H. Greenberg, H.A. Kopelen, C. Koilpillat, M.C. Limmacher, and D.M. Shindler Echocardiographic predictors of clinical outcomes in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy J Am Coll Cardiol 35 2000 1237 1244
6. M. Bikkina, M.G. Karson, and D. Levy Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy J Am Coll Cardiol 22 1993 1111 1116
7. P. Spirito, P. Bellone, K.M. Harris, P. Bernabo, P. Bruzzi, and B.J. Maron Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy N Engl J Med 342 2000 1778 1785
8. R.B. Devereux, and N. Reichek Echocardiographic determination of left ventricular mass in man: anatomical validation of a method Circulation 55 1977 613 618
9. W. Grossman, D. Jones, and L.P. McLaurin Wall stress and patterns of hypertrophy in the human left ventricle J Clin Invest 56 1989 56 64
10. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease J Clin Invest 117 2007 568 575
11. K.T. Weber Cardiac insterstitium in health and disease: the fibrillar collagen network J Am Coll Cardiol 13 1989 1637 1652
12. P. Verdecchia, F. Angeli, C. Borgioni, R. Gattobigio, G. de Simone, and R.B. Devereux Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis Am J Hypertens 16 2003 895 899
13. R.B. Devereux, K. Wachtell, E. Gerdts, K. Boman, M.S. Nieminen, and V. Papademetriou Prognostic significance of left ventricular mass change during treatment of hypertension: the LIFE study JAMA 292 2004 2350 2356
14. J.M. Gardin, and M.S. Lauer Left ventricular hypertrophy: the next treatable silent killer? JAMA 292 2004 2396 2398
15. B. Dahlöf, K. Pennert, and L. Hansson Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies Am J Hypertens 5 1992 95 110
16. R.B. Devereux, V. Palmieri, J.E. Liu, K. Wachtell, J.N. Bella, and K. Boman Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention for Endpoint Reduction Study J Hypertens 20 2002 1445 1450 (Pubitemid 34925691)
17. M. Moser, and P.R. Herbert Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials J Am Coll Cardiol 27 1996 1214 1218
18. J.M. Cruickshank, J. Lewis, V. Moore, and C. Dodd Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy J Hum Hypertens 6 1992 85 90
19. D.J. Sheridan Regression of left ventricular hypertrophy: do antihypertensive classes differ? J Hypertens Suppl 18 2000 S21 S27
20. J.A. Diamond, and R.A. Philips Regression of left ventricular hypertrophy: are there preferred drugs? Curr Hypertens Rep 5 2003 368 371
21. R. Zhang, J. Crump, and E. Reisen Regression of left ventricular hypertrophy is a key goal of hypertension management Curr Hypertens Reports 5 2003 301 308
22. L.M. Ruilope, and R.E. Schmieder Left ventricular hypertrophy and clinical outcomes in hypertensive patients Am J Hypertens 21 2008 500 508
23. A.U. Klingbeil, M. Schneider, P. Martus, F.H. Messerli, and R.E. Schmieder A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension Am J Med 115 2003 41 46
24. F.H. Messerli, and E. Grossman B-blockers in hypertension: is carvedilol different? Am J Cardiol 93 Suppl 9A 2004 7B 12B
25. H.J. Why, and P.J. Richardson Effect of carvedilol on left ventricular function and mass in hypertension J Cardiovascular Pharmacol 199 1992 S50 S54
26. M. Verza, S. Ammendola, A. Gambardella, G. Scot, S. Vesico, and R. Totoriello Regression of left ventricular hypertrophy in hypertensive elderly patient with carvedilol Arch Gerontol Geriatr 22 1996 143 147
27. M.S. Lauer, K.M. Anderson, M.G. Larson, and D. Levy A new method for indexing left ventricular mass difference in body size Am J Cardiol 74 1994 487 491
28. G.L. Bakris, E.A. Tarka, B. Waterhouse, M.R. Goulding, A. Madan, and K.M. Anderson Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile Am J Cardiol 98 suppl 2006 46L 52L
29. M.G. St John Sutton, T. Plappert, W.T. Abraham, A.L. Smith, D.B. DeLugio, and A.R. Leon Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure Circulation 107 2003 1985 1990
30. M. St John Sutton, D. Lee, J.L. Rouleau, S. Goldman, T. Plappert, and E. Braunwald Left ventricular remodeling and ventricular arrhythmias after myocardial infarction Circulation 107 2003 2577 2582
31. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the American College of Cardiology Echocardiography Committee, the American Heart Association, and the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
32. N. Reichek, J. Helak, T. Plappert, M.S. Sutton, and K.T. Weber Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results Circulation 67 1983 348 352
33. J.W. Helak, T. Plappert, A. Muhammad, and N. Reichek Two dimensional echographic imaging of the left ventricle: comparison of mechanical and phased array systems in vitro Am J Cardiol 48 1981 728 735
34. R.B. Devereux, D.R. Alonso, E.M. Lutas, G.J. Gottlieb, E. Campo, and I. Sachs Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings Am J Cardiol 57 1986 450 458
35. N. Reichek, and D. Gupta Left ventricular volumes, ejection fraction, mass and shape C. Kramer, W.G. Hundley, Atlas of cardiovascular magnetic resonance imaging: an imaging companion to Braunwald's heart disease 2010 Saunders Elsevier Philadelphia 35
36. N. Reichek, R.B. Devereux, R.A. Rocha, R. Hilkert, D. Hall, and D. Purkayastha Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension Hypertension 54 2009 731 737
37. M. Janik, M.D. Cham, M.I. Ross, Y. Wang, N. Codella, and J.K. Min Effects of papillary muscles and trabeculae on left ventricular quantification: increased impact of methodological variability in patients with left ventricular hypertrophy J Hypertens 26 2008 1677 1685
38. J.W. Weinsaft, M.D. Cham, M. Janik, J.K. Min, C.I. Henschke, and D.F. Yankelevitz Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: effects on clinical standards in patients with advanced systolic dysfunction Int J Cardiol 126 2008 359 365
39. X. Zhou, and E.D. Frohlich Physiologic evidence of renoprotection by antihypertensive therapy Curr Opin Cardiol 20 2005 290 295
40. P.D. Hart, and G.L. Bakris Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol 27 2007 555 564
41. R.E. Schmieder, P. Martus, and A. Klingbeil Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies JAMA 275 1996 1507 1513
42. R.H. Fagard, H. Celis, L. Thijs, and S. Wouters Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies Hypertension 54 2009 1084 1091
43. J.A. Diamond, and R.A. Philips Hypertensive heart disease Hypertens Res 28 2005 191 202
44. R.B. Devereux, V. Palmieri, N. Sharpe, V. De Quattro, J.N. Bella, and G. de Simone Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension Circulation 104 2001 1248 1254